ATP6V1A and neoplasm: Given the role of CLC3 in promoting chemoresistance, lysosomal function, and tumor stemness, targeting CLC3 or its downstream effectors, such as V-ATPase—especially ATP6V1A—may represent a promising therapeutic strategy.